Summary

Location
at UCLA
Dates
study started
estimated completion

Description

Summary

The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.

Keywords

Chronic Lymphocytic Leukemia Acute Myeloid Leukemia Multiple Myeloma Non-Hodgkin's Lymphoma Acute Lymphoblastic Leukemia Cancer Chronic Lymphocytic Leukemia (CLL) Acute Myeloid Leukemia (AML) Multiple Myeloma (MM) Non-Hodgkin's Lymphoma (NHL) Acute Lymphoblastic Leukemia (ALL) Venetoclax Leukemia Leukemia, Myeloid, Acute Lymphoma, Non-Hodgkin Leukemia, Lymphoid Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphocytic, Chronic, B-Cell

Eligibility

You can join if…

  • Subject has been enrolled and dosed in an ongoing venetoclax study and continues to tolerate and derive benefit from the study drug.
  • Male subject agrees to refrain from sperm donation.
  • Female subjects must not be pregnant or breastfeeding.

You CAN'T join if...

  • None.

Locations

  • UCLA Santa Monica Hematology Oncology /ID# 210551
    Los Angeles California 90095-2000 United States
  • University of Arizona Cancer Center - Tucson /ID# 210548
    Tucson Arizona 85724 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
Links
This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.
ID
NCT03844048
Phase
Phase 3
Study Type
Interventional
Last Updated